top of page


AI-CVD Summary
Coronary Calcification
Aortic Calcification
Epicardial Fat
Cardiac Chambers
Aorta & PA Size
Lung LAI
Lung HAI
Liver Fat
Muscle & Visceral Fat
Bone Density











































































News and Updates


HeartLung.AI to Present Eight Abstracts at AHA 2026, Advancing a New Era of Preventive Screening
PRESS RELEASE | SCIENTIFIC SESSIONS 2026 EMBARGOED UNTIL MONDAY, NOVEMBER 2, 2026 • 4:00 A.M. CENTRAL TIME Research spans coronary plaque, Agatston-2.0, cardiac chambers, lung cancer and chest X-ray AI; visit Booth 641 throughout the Chicago exhibits. Chicago, Illinois — November 2, 2026 — HeartLung Corporation (HeartLung.AI) will present eight accepted scientific abstracts at the American Heart Association (AHA) Scientific Sessions 2026, taking place November 6–9 at McCor
Nov 34 min read


HeartLung.AI Showcases 10 Scientific Presentations at ESC Congress 2026, Advancing AI-Powered Cardiovascular and Lung Imaging
Company-record scientific program shows how AI can uncover coronary, chamber, valvular, plaque and lung cancer risk insights from routine CT. MUNICH, Germany, September 1, 2026- HeartLung.AI today announced the successful completion of a company-record scientific program at ESC Congress 2026 in Munich, where its investigators and academic collaborators presented 10 studies advancing artificial intelligence for cardiovascular prevention, coronary calcium assessment, cardiac ch
Sep 19 min read


RSNA Features HeartLung.AI Study Linking AI-Quantified Myosteatosis to Future COPD Risk
20-year MESA analysis finds CT-derived muscle quality predicts COPD more strongly than emphysema-like lung measures. HOUSTON, Texas - August 7, 2026 - HeartLung.AI today announced that the Radiological Society of North America (RSNA) has featured a major research publication demonstrating the potential of artificial intelligence-derived myosteatosis measurements from coronary artery calcium (CAC) CT scans to predict future chronic obstructive pulmonary disease (COPD). The ded
Aug 74 min read


Two HeartLung.AI Studies Show Routine Chest CT Can Assess Cardiac Risk Comparably to Dedicated Cardiac CT and Echocardiography
Complementary MESA analyses validate AI-derived cardiac chamber volumetry from non-gated, non-contrast CT for opportunistic heart failure and atrial fibrillation risk assessment HOUSTON - July 16, 2026 - HeartLung.AI announced the acceptance of two complementary studies in the American Journal of Preventive Cardiology demonstrating that artificial intelligence can extract clinically meaningful cardiac chamber measurements from routine non-gated, non-contrast chest CT and asse
Jul 164 min read


HeartLung Launches "Why Pay More and Get Less?" Campaign at SCCT 2026
Campaign contrasts coronary plaque-centric AI-CCTA marketing with AI-CVD's CAC-based, whole-patient primary prevention approach: one lower-cost, lower-radiation, non-contrast CT scan, 10+ actionable reports, and broader cardiovascular and cardiometabolic risk phenotyping. SAN DIEGO, July 6, 2026 - HeartLung Corporation (HeartLung.AI), a medical AI company transforming CT imaging into preventive care intelligence, today announced the launch of its "Why Pay More and Get Less?"
Jul 75 min read


AHA Stroke Alert Podcast Features HeartLung.AI Research on AI-Predicted Atrial Fibrillation and Stroke
AI-derived left atrial volume and chamber ratios from CAC scans predicted long-term AF and stroke in MESA and Framingham. HOUSTON, June 18, 2026 - HeartLung.AI today announced that its research article, "AI-Derived LA Volume Index, LA/RA and LA/LV Volume Ratios From Coronary Artery Calcium Scans Predict Long-Term Atrial Fibrillation and Stroke," was featured on the June 2026 episode of the Stroke Alert Podcast, the podcast of Stroke, a journal of the American Heart Associatio
Jun 193 min read


After 36 Years, the Legendary Agatston Score Gets Its First Major AI Upgrade
New peer-reviewed study introduces Agatston-2.0, led by Morteza Naghavi, MD, with Arthur S. Agatston, MD, the originator of the original Agatston score, and leading cardiovascular imaging and prevention experts. HOUSTON, TX, June 2026 — HeartLung Corporation today announced the publication of a landmark peer-reviewed study introducing Agatston-2.0, a next-generation artificial intelligence-based coronary artery calcium scoring method designed to modernize one of the most infl
Jun 127 min read


Study Shows AI-CVD® Outperforms Diabetes in Predicting Heart Failure Risk
HOUSTON, TX, May 18, 2026 - HeartLung Corporation announced the publication of a new study in the American Journal of Preventive Cardiology titled “Comparing Incidence of Heart Failure in Individuals with Enlarged Cardiac Chambers versus Diabetes.” The study demonstrates that HeartLung’s AI-CVD AutoChamber module can opportunistically identify left atrial enlargement, left ventricular enlargement, and increased left ventricular mass from routine coronary artery calcium scans,
May 184 min read


HeartLung.AI Emerges as a Leading Innovator in Cardiology with 10 Accepted ESC.26 Abstracts
Accepted studies showcase HeartLung.AI’s leadership in AI-CVD, opportunistic CT screening, Agatston 2.0, chamber volumetry, and preventive cardiology. HOUSTON, Texas, 05/11/2026 – HeartLung.AI today announced that 10 scientific abstracts have been accepted for presentation at ESC Congress 2026, the annual meeting of the European Society of Cardiology. The accepted studies showcase HeartLung.AI’s growing leadership in AI–enabled cardiovascular imaging and preventive cardiology
May 118 min read


HeartLung Announces USPTO Issuance of Foundational AI-CVD Patent and Allowance for Vasa Vasorum Inflammation Imaging
New intellectual property milestones strengthen HeartLung’s leadership in AI–enabled preventive CT imaging and coronary inflammation assessment HOUSTON, TX, UNITED STATES, May 3, 2026 /EINPresswire.com/ -- HeartLung Corporation, a medical technology company advancing AI–enabled, CT–based opportunistic screening and early disease detection, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 12,620,494, titled “Predicting adverse healt
May 43 min read
Updates from 'X' (Twitter)
Ready to Unlock the Value in Your CT Scans?
Join leading healthcare providers using AI-CVD to save lives and increase revenue, and lead the future of preventive cardiology.

bottom of page

